SCHEMBL2188667

SCHEMBL2188667

CC(C)([C@H]1CCN(c2ccc(-c3ccncc3)cc2)C(=O)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.45
CACNA1B Q00975 2/20 0.45
NR1I2 O75469 1/20 0.45
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
GRM5 P41594 1/20 0.37
KMT2A Q03164 1/20 0.37
HTR6 P50406 1/20 0.37
CYP17A1 P05093 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
FPR2 P25090 2/20 0.36
FPR1 P21462 1/20 0.36
GPR142 Q7Z601 1/20 0.36
CTPS1 P17812 1/20 0.36
HSD11B1 P28845 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2188926 1.00 CYP3A4 (0.45) CYP3A4CACNA1BNR1I2ROCK2ROCK1
SCHEMBL2190018 0.91 CACNA1B (0.49) CYP3A4CACNA1BNR1I2KMT2AHTR6
SCHEMBL2191790 0.91 CACNA1B (0.49) CYP3A4CACNA1BNR1I2KMT2AHTR6
SCHEMBL2188835 0.91 CACNA1B (0.49) CYP3A4CACNA1BNR1I2KMT2AHTR6
SCHEMBL12415567 0.91 CYP11B1 (0.47) CYP3A4CACNA1BNR1I2GRM5KMT2A
SCHEMBL12415565 0.91 CYP11B1 (0.47) CYP3A4CACNA1BNR1I2GRM5KMT2A
SCHEMBL12415571 0.91 CYP3A4 (0.43) CYP3A4CACNA1BNR1I2GRM5KMT2A
SCHEMBL12415578 0.91 CYP3A4 (0.43) CYP3A4CACNA1BNR1I2GRM5KMT2A
SCHEMBL2191556 0.88 CYP3A4 (0.42) CYP3A4CACNA1BNR1I2GRM5KMT2A
SCHEMBL2190172 0.88 CYP3A4 (0.42) CYP3A4CACNA1BNR1I2GRM5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CYP3A4 939/4885CACNA1B 23/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.